RemeGen Focused on Growing Domestic Business
Share
Shaojing Tong, CFO at Chinese biotech firm RemeGen, discusses the company's first quarter results and shares his confidence in growth in the domestic market. The company's stock has outperformed all of its peers in the MSCI China Healthcare Index since the start of the year.